Cargando…
Peroxisome Proliferator-Activated Receptor α (PPARα) down-regulation in cystic fibrosis lymphocytes
BACKGROUND: PPARs exhibit anti-inflammatory capacities and are potential modulators of the inflammatory response. We hypothesized that their expression and/or function may be altered in cystic fibrosis (CF), a disorder characterized by an excessive host inflammatory response. METHODS: PPARα, β and γ...
Autores principales: | , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1562413/ https://www.ncbi.nlm.nih.gov/pubmed/16875506 http://dx.doi.org/10.1186/1465-9921-7-104 |
_version_ | 1782129496968658944 |
---|---|
author | Reynders, Veerle Loitsch, Stefan Steinhauer, Constanze Wagner, Thomas Steinhilber, Dieter Bargon, Joachim |
author_facet | Reynders, Veerle Loitsch, Stefan Steinhauer, Constanze Wagner, Thomas Steinhilber, Dieter Bargon, Joachim |
author_sort | Reynders, Veerle |
collection | PubMed |
description | BACKGROUND: PPARs exhibit anti-inflammatory capacities and are potential modulators of the inflammatory response. We hypothesized that their expression and/or function may be altered in cystic fibrosis (CF), a disorder characterized by an excessive host inflammatory response. METHODS: PPARα, β and γ mRNA levels were measured in peripheral blood cells of CF patients and healthy subjects via RT-PCR. PPARα protein expression and subcellular localization was determined via western blot and immunofluorescence, respectively. The activity of PPARα was analyzed by gel shift assay. RESULTS: In lymphocytes, the expression of PPARα mRNA, but not of PPARβ, was reduced (-37%; p < 0.002) in CF patients compared with healthy persons and was therefore further analyzed. A similar reduction of PPARα was observed at protein level (-26%; p < 0.05). The transcription factor was mainly expressed in the cytosol of lymphocytes, with low expression in the nucleus. Moreover, DNA binding activity of the transcription factor was 36% less in lymphocytes of patients (p < 0.01). For PPARα and PPARβ mRNA expression in monocytes and neutrophils, no significant differences were observed between CF patients and healthy persons. In all cells, PPARγ mRNA levels were below the detection limit. CONCLUSION: Lymphocytes are important regulators of the inflammatory response by releasing cytokines and antibodies. The diminished lymphocytic expression and activity of PPARα may therefore contribute to the inflammatory processes that are observed in CF. |
format | Text |
id | pubmed-1562413 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2006 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-15624132006-09-08 Peroxisome Proliferator-Activated Receptor α (PPARα) down-regulation in cystic fibrosis lymphocytes Reynders, Veerle Loitsch, Stefan Steinhauer, Constanze Wagner, Thomas Steinhilber, Dieter Bargon, Joachim Respir Res Research BACKGROUND: PPARs exhibit anti-inflammatory capacities and are potential modulators of the inflammatory response. We hypothesized that their expression and/or function may be altered in cystic fibrosis (CF), a disorder characterized by an excessive host inflammatory response. METHODS: PPARα, β and γ mRNA levels were measured in peripheral blood cells of CF patients and healthy subjects via RT-PCR. PPARα protein expression and subcellular localization was determined via western blot and immunofluorescence, respectively. The activity of PPARα was analyzed by gel shift assay. RESULTS: In lymphocytes, the expression of PPARα mRNA, but not of PPARβ, was reduced (-37%; p < 0.002) in CF patients compared with healthy persons and was therefore further analyzed. A similar reduction of PPARα was observed at protein level (-26%; p < 0.05). The transcription factor was mainly expressed in the cytosol of lymphocytes, with low expression in the nucleus. Moreover, DNA binding activity of the transcription factor was 36% less in lymphocytes of patients (p < 0.01). For PPARα and PPARβ mRNA expression in monocytes and neutrophils, no significant differences were observed between CF patients and healthy persons. In all cells, PPARγ mRNA levels were below the detection limit. CONCLUSION: Lymphocytes are important regulators of the inflammatory response by releasing cytokines and antibodies. The diminished lymphocytic expression and activity of PPARα may therefore contribute to the inflammatory processes that are observed in CF. BioMed Central 2006 2006-07-30 /pmc/articles/PMC1562413/ /pubmed/16875506 http://dx.doi.org/10.1186/1465-9921-7-104 Text en Copyright © 2006 Reynders et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Reynders, Veerle Loitsch, Stefan Steinhauer, Constanze Wagner, Thomas Steinhilber, Dieter Bargon, Joachim Peroxisome Proliferator-Activated Receptor α (PPARα) down-regulation in cystic fibrosis lymphocytes |
title | Peroxisome Proliferator-Activated Receptor α (PPARα) down-regulation in cystic fibrosis lymphocytes |
title_full | Peroxisome Proliferator-Activated Receptor α (PPARα) down-regulation in cystic fibrosis lymphocytes |
title_fullStr | Peroxisome Proliferator-Activated Receptor α (PPARα) down-regulation in cystic fibrosis lymphocytes |
title_full_unstemmed | Peroxisome Proliferator-Activated Receptor α (PPARα) down-regulation in cystic fibrosis lymphocytes |
title_short | Peroxisome Proliferator-Activated Receptor α (PPARα) down-regulation in cystic fibrosis lymphocytes |
title_sort | peroxisome proliferator-activated receptor α (pparα) down-regulation in cystic fibrosis lymphocytes |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1562413/ https://www.ncbi.nlm.nih.gov/pubmed/16875506 http://dx.doi.org/10.1186/1465-9921-7-104 |
work_keys_str_mv | AT reyndersveerle peroxisomeproliferatoractivatedreceptorapparadownregulationincysticfibrosislymphocytes AT loitschstefan peroxisomeproliferatoractivatedreceptorapparadownregulationincysticfibrosislymphocytes AT steinhauerconstanze peroxisomeproliferatoractivatedreceptorapparadownregulationincysticfibrosislymphocytes AT wagnerthomas peroxisomeproliferatoractivatedreceptorapparadownregulationincysticfibrosislymphocytes AT steinhilberdieter peroxisomeproliferatoractivatedreceptorapparadownregulationincysticfibrosislymphocytes AT bargonjoachim peroxisomeproliferatoractivatedreceptorapparadownregulationincysticfibrosislymphocytes |